JP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Neutral 69.2%

Neg 0% Neu 69.2% Pos 0%

JP Morgan analyst Joyce Zhou initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Overweight rating and announces Price Target of $12.